Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587351 · ClinicalTrials.gov registry record · Phase 3
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 3
- Development phase
- 532
- Enrollment target
NCT02587351: Clinical Trial Phase 3 study, sponsored by University of Minnesota.
NCT02587351 is a Phase 3 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 532 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02587351, a Phase 3 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 532 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one year. The primary endpoint is time to first acute exacerbation. Secondary endpoints include rates and severity of COPD exacerbations, cardiovascular events, all-cause mortality, lung function, dyspnea, quality of life and metoprolol-related side effects.
Primary Outcome
Acute exacerbations are defined as a "complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days".
Interventions
- OTHER Placebo
- DRUG Metoprolol succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 3 |
Why NCT02587351 stopped before completion
NCT02587351 is an interventional study that assigns participants to a tested intervention. The registered 532 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02587351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02587351 about?
NCT02587351 is a clinical study titled "Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease". This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one year. The primary endpoint is time to first acute exacerbation. Secondary e...
What is the current status of trial NCT02587351?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 532 participants. The study started on 2016-05-01. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02587351?
The interventions under investigation include: Placebo (OTHER), Metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT02587351?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02587351's enrollment target sits among peer trials
532 704th of 2000 higher than 1,297 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- NCT07219173 · 531 participants · Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI